Linex Forte caps. # 14
Package quantity, pcs:
7
14
Category
Preparations for the gastrointestinal tract
Scope of the drug
Gastrointestinal tract
Release form
Capsules
Manufacturer country
Slovenia
Package quantity, pcs
14
Release form, composition and packaging
?
Opaque capsules, white body, yellow cap
the contents of the capsules are light beige powder interspersed with yellow.
1 caps.
powder Probio-tec AB Blend 64 (Probio-tec® AB Blend 64) 60 mg,
incl.
Lactobacillus acidophilus (LA-5) 13.8 mg
Bifidobacterium animalis subsp.
lactis (BB-12) 4.2 mg
Auxiliary components of the active ingredient: anhydrous dextrose - 29.1 mg, microcrystalline cellulose - 6 mg, potato starch - 6 mg, magnesium stearate - 0.9 mg.
Beneo Synergy 1 (Beneo® Synergy 1) - 171.5 mg (powder contains 90-94% inulin and 6-10% oligofructose (dextrose + fructose + sucrose)), magnesium stearate - 3.5 mg.
The composition of the capsule body: hypromellose - 33.149 mg, titanium dioxide (E171) - 0.691 mg.
The composition of the capsule cap: hypromellose - 22.08 mg, titanium dioxide (E171) - 0.24 mg, iron dye yellow oxide (E172) - 0.24 mg.
7 pcs.
- blisters (1) - cardboard packs.
7 pcs.
- blisters (2) - cardboard packs.
pharmachologic effect
The drug normalizes the intestinal microflora. One capsule of Linex Forte contains 2 × 109 colony-forming units of live lyophilized lactic acid bacteria: Lactobacillus acidophilus (LA-5) and Bifidobacterium animalis subsp. lactis (BB-12). Live lactic acid bacteria are a normal component of the natural intestinal microflora. Lactic acid bacteria perform a protective function, synthesizing substances with antibacterial activity, producing enzymes, under the influence of which hydrolysis of fiber, proteins, fats, starch and deconjugation of bile acids occurs, and also participate in the synthesis of vitamins of group B, C, K, amino acids, organic acids. Lactic acid bacteria LA-5 and BB-12 inhibit the growth of pathogenic bacteria by:- shift of intestinal pH to the acidic side (the result of the ability of LA-5 to synthesize lactic acid and BB-12 to synthesize acetic and succinic acids in addition to lactic acid) - production of metabolites that have a toxic effect on pathogenic bacteria (formation of H2O2) - the formation of antimicrobial substances, bacteriocins (LA-5 secretes acidocin, a broad-spectrum bacteriocin that prevents the growth of bacteria and fungi) - competition with pathogenic bacteria for nutrients - interactions with adhesion receptors, thus preventing the colonization of other, potentially pathogenic microorganisms.- the formation of antimicrobial substances, bacteriocins (LA-5 secretes acidocin, a broad-spectrum bacteriocin that prevents the growth of bacteria and fungi) - competition with pathogenic bacteria for nutrients - interactions with adhesion receptors, thus preventing the colonization of other, potentially pathogenic microorganisms.- the formation of antimicrobial substances, bacteriocins (LA-5 secretes acidocin, a broad-spectrum bacteriocin that prevents the growth of bacteria and fungi) - competition with pathogenic bacteria for nutrients - interactions with adhesion receptors, thus preventing the colonization of other, potentially pathogenic microorganisms.
Pharmacokinetics
Lactic acid bacteria, such as LA-5 and BB-12, act directly in the gastrointestinal tract when taken orally, the drug does not undergo systemic absorption.
Routine pharmacokinetic studies are therefore not applicable.
The resistance of LA-5 and BB-12 to the effects of gastric juice and bile allows the strains in large quantities to remain viable when passing through the stomach and duodenum.
Both strains attach to the intestinal mucosa.
Like other microorganisms, it is gradually excreted from the gastrointestinal tract with feces.
Indications for use
- treatment and prevention of intestinal dysbiosis.
Intestinal dysbiosis is manifested by the following symptoms: diarrhea, dyspepsia, constipation, flatulence, nausea, belching, vomiting, abdominal pain, allergic skin reactions are possible.
- Relief of constipation in adults and children over 12 years old
- an addition to the standard eradication therapy of Helicobacter pylori in adults and children over 12 years old.
Contraindications for use
- hereditary fructose intolerance, sucrase-isomaltase deficiency or glucose / galactose malabsorption syndrome
- hypersensitivity to drug components.
The drug should be used with caution in diabetes mellitus (it contains simple sugars), deficiency of the immune system (for example, HIV infection).
Dosage regimen
The drug is taken orally, preferably during or after meals.
The capsules should be taken with a small
Name ENG
LINEX FORTE
Clinical and pharmacological group
A drug that regulates the balance of intestinal microflora (probiotic)
ATX code
Preparations containing microorganisms that produce lactic acid in combination with other drugs
Dosage
60mg
Structure
1 capsule contains: Active ingredient: Probio-tec AB Blend 64 powder - 60,000 mg (powder contains active ingredients: Lactobacillus acidophilus (LA-5) - 13.8 mg and Bifidobacterium animalis subsp.lactis ( BB-12) - 4.2 mg auxiliary components: anhydrous dextrose - 29.1 mg, microcrystalline cellulose - 6 mg, potato starch 6 - mg, magnesium stearate - 0.9 mg).
Excipients: Beneo Synergy 1 - 171,500 mg (powder contains 90-94% inulin and 6-10% oligofructose (dextrose + fructose + sucrose))
magnesium stearate - 3,500 mg.
The composition of the capsule body: hypromellose - 33.149 mg, titanium dioxide (E 171) - 0.691 mg.
The composition of the capsule cap: hypromellose - 22.080 mg, titanium dioxide dye (E 171) - 0.240 mg, iron dye yellow oxide (E 172) - 0.240 mg.
Indications
treatment and prevention of intestinal dysbiosis.
Intestinal dysbiosis is manifested by the following symptoms: diarrhea, dyspepsia, constipation, flatulence, nausea, belching, vomiting, abdominal pain, allergic skin reactions are possible.
relief of constipation in adults and children over 12 years of age
addition to standard eradication therapy of Helicobacter pylori in adults and children over 12 years old.
Storage conditions and periods
At a temperature not higher than 25 degrees.
Expiration date: 2 years
Contraindications
hereditary fructose intolerance, sucrase-isomaltase deficiency or glucose / galactose malabsorption syndrome
hypersensitivity to drug components.
The drug should be used with caution in diabetes mellitus (it contains simple sugars), deficiency of the immune system (for example, HIV infection).
INN / Active ingredient
Lactobacillus acidophilus, Bifidobacterium animalis subsp.
lactis
Specifications
Category
Preparations for the gastrointestinal tract
Scope of the drug
Gastrointestinal tract
Release form
Capsules
Manufacturer country
Slovenia
Package quantity, pcs
14
Scope of application
Gastroenterology
Minimum age from
From birth
Way of introduction
Through the mouth
Vacation conditions
Without recipe
Brand name
Sandoz
The amount of the dosage form in the primary package
7 pcs.
Primary packaging type
Blister
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
Eubiotic
Dosage form
Capsules
The target audience
Children
Dosage (volume) of the substance in the preparation
60mg
Expiration date in days
730
Package weight, g
45
Mode of application
:
Linex Forte capsules are preferably taken with or after meals, with a little liquid. < br> < br> Adults and adolescents over 12 years old: 1 capsule 1-3 times a day. < br> < br> Children from 2 to 12 years: 1 capsule 1-2 times a day. < br> < br> Newborns and children under 2 years of age: 1 capsule once a day. < br> < br> Diarrhea in children under 6 years old should be treated under medical supervision. < br> < br> When Linex Forte is prescribed to children and patients who cannot swallow a whole capsule, it must be opened, the contents are poured into a spoon and mixed with a small amount of liquid. < br> < br> The duration of treatment depends on the cause development of dysbiosis and individual characteristics of the organism. Linex Forte can be taken until the symptoms of dysbiosis disappear. < br> < br> Do not exceed the recommended daily dose of the drug.
Anatomical and therapeutic characteristics
:
A07FA51 Microorganisms producing lactic acid, in combination with other drugs
Information on technical characteristics, delivery set, country of manufacture